Edwards Lifesciences Sees Q4 EPS $0.53-$0.57; Sales $1.33B-$1.39B
Portfolio Pulse from Benzinga Newsdesk
Edwards Lifesciences has provided guidance for Q4, expecting earnings per share (EPS) between $0.53 and $0.57 and sales between $1.33 billion and $1.39 billion.
October 24, 2024 | 8:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Edwards Lifesciences has issued Q4 guidance with EPS expected between $0.53 and $0.57 and sales between $1.33 billion and $1.39 billion.
The guidance provided by Edwards Lifesciences suggests a positive outlook for the company's financial performance in Q4. The expected EPS and sales figures indicate potential growth, which could positively influence investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100